Table 1.
Clinical characteristics of patients.
| Age at diagnosis | Sex | Stage at diagnosis | Previous Therapies and Response | Disease status at ASCT | Stage at ASCT | Extranodal disease at ASCT | |||
|---|---|---|---|---|---|---|---|---|---|
| ALL PATIENTS (n=9) | 28.5 | Female: 5/9 | II: 4/9 | – | 9/9 PD | IV: 9/9 | Multiple in 7/9 | ||
| (median) | Male: 4/9 | III: 1/9 | Single in 2/9 | ||||||
| IV: 4/9 | |||||||||
| Patient #1 | 26 | F | IIB | 2xABVD-> PD | PD | IVB | Lung, liver | ||
| 2xIGeV-> PD | |||||||||
| 4xBV-> PD | |||||||||
| Patient #2 | 19 | M | IIA | 2xABVD-> PR | PD | IVA | Lung, pericardium | ||
| 2xIGeV-> NR | |||||||||
| 4xBV-> PD | |||||||||
| Patient #3 | 56 | M | IIA | 6xABVD-> PD | PD | IVA | Lung | ||
| 2xIGeV-> NR | |||||||||
| 4xBV-> PD | |||||||||
| Patient #4 | 32 | F | IVA | 6xABVD-> PD | PD | IVB | Lung, liver | ||
| 4xIGeV-> NR | |||||||||
| 4xBV-> PD | |||||||||
| Patient #5 | 22 | F | IVB | 6xABVD-> PD | PD | IVB | Lung, liver, bone | ||
| 3xBeGeV-> PD | |||||||||
| 4x BV-> PD | |||||||||
| Patient #6 | 37 | F | IIB | 2xABVD-> PR | PD | IVB | Lung, bone | ||
| 4xIGeV-> PD | |||||||||
| 4xBV-> PD | |||||||||
| Patient #7 | 31 | F | IIIB | 2xABVD->PD | PD | IVB | Lung, pancreatic | ||
| 4xBeGeV->RP | |||||||||
| 4xBV-> PD | |||||||||
| Patient #8 | 20 | M | IVB | 2xABVD->PR | PD | IVB | Lung, bone, bone marrow | ||
| 4xBeGeV-> NR | |||||||||
| 4xBV-> PD | |||||||||
| Patient #9 | 65 | M | IIA | 2xABVD->RP | PD | IVB | Lung | ||
| 3xBeGeV-> NR | |||||||||
| 4xBV->PD | |||||||||
| Control #1 | 52 | F | IIB | 2xABVD-> PR | CR | – | – | ||
| 4xIGeV-> CR | |||||||||
| Control #2 | 34 | F | IIIA | 6xABVD-> PD | CR | – | – | ||
| 4xIGeV-> CR | |||||||||
| Control #3 | 63 | F | IIIA | 2xABVD-> PD | CR | – | – | ||
| 4xBeGeV-> SD | |||||||||
| 2xBV-> CR | |||||||||